CYP2C19*17 is associated with decreased breast cancer risk

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 391-396

  Justenhoven, Christina ^a,b   Hamann, Ute ^c   Pierl, Christiane B ^d   Baisch, Christian ^e   Harth, Volker ^f   Rabstein, Sylvia ^f   Spickenheuer, Anne ^f   Pesch, Beate ^f   Brüning, Thomas ^f   Winter, Stefan ^a,b,g   Ko, Yon Dschun ^e   Brauch, Hiltrud ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Institute for Occupational Epidemiology and Risk Assessment   (Germany)

^e Johanniter Krankenhaus   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Breast cancer; CYP2C19*Polymorphisms; Hormone therapy

Indexed keywords

CYTOCHROME P450 2C19; ESTROGEN; CYP2C19 PROTEIN, HUMAN; TUMOR MARKER; UNSPECIFIC MONOOXYGENASE;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CATABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; FEMALE; GENOTYPE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLISM; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; MASS SPECTROMETRY; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67349157649     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0076-4     Document Type: Article

References (23)

1. TJ Key NE Allen EA Spencer RC Travis 2002 The effect of diet on risk of cancer Lancet 360 861 868 10.1016/S0140-6736(02)09958-0
2. EJ Folkerd LA Martin A Kendall M Dowsett 2006 The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer J Steroid Biochem Mol Biol 102 250 255 10.1016/j.jsbmb.2006.09.024
3. C Justenhoven U Hamann F Schubert M Zapatka CB Pierl S Rabstein 2008 Breast cancer: a candidate gene approach across the estrogen metabolic pathway Breast Cancer Res Treat 108 137 149
4. ZN Cheng Y Shu ZQ Liu LS Wang DS Ou-Yang HH Zhou 2001 Role of cytochrome P450 in estradiol metabolism in vitro Acta Pharmacol Sin 22 148 154
5. AE Cribb MJ Knight D Dryer J Guernsey K Hender M Tesch 2006 Role of polymorphic human cytochrome P450 enzymes in estrone oxidation Cancer Epidemiol Biomarkers Prev 15 551 558 10.1158/1055-9965.EPI-05-0801
6. T Furuta K Ohashi T Kamata M Takashima K Kosuge T Kawasaki 1998 Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Ann Intern Med 129 1027 1030
7. T Furuta N Shirai F Watanabe S Honda K Takeuchi T Iida 2002 Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Clin Pharmacol Ther 72 453 460 10.1067/mcp.2002.127637
8. T Furuta N Shirai M Sugimoto K Ohashi T Ishizaki 2004 Pharmacogenomics of proton pump inhibitors Pharmacogenomics 5 181 202 10.1517/phgs.5.2.181.27483
9. M Kawamura S Ohara T Koike K Iijima J Suzuki S Kayaba 2003 The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism Aliment Pharmacol Ther 17 965 973 10.1046/j.1365-2036.2003.01539.x
10. J Kirchheiner K Nickchen M Bauer ML Wong J Licinio I Roots 2004 Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 442 473 10.1038/sj.mp.4001494
11. W Schroth L Antoniadou P Fritz M Schwab T Muerdter UM Zanger 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 10.1200/JCO.2007.12.2705
12. SM De Morais JA Goldstein HG Xie SL Huang YQ Lu H Xia 1995 Genetic analysis of the S-mephenytoin polymorphism in a Chinese population Clin Pharmacol Ther 58 404 411 10.1016/0009-9236(95)90053-5
13. PJ Wedlund 2000 The CYP2C19 enzyme polymorphism Pharmacology 61 174 183 10.1159/000028398
14. SM De Morais GR Wilkinson J Blaisdell UA Meyer K Nakamura JA Goldstein 1994 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 594 598
15. PL Roddam S Rollinson E Kane E Roman A Moorman R Cartwright 2000 Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia Pharmacogenetics 10 605 615 10.1097/00008571-200010000-00004
16. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113 10.1016/j.clpt.2005.10.002
17. C Justenhoven U Hamann B Pesch V Harth S Rabstein C Baisch 2004 ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population Cancer Epidemiol Biomarkers Prev 13 2059 2064
18. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U et al (2007) The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-007-9762-x
19. B Pesch Y Ko H Brauch U Hamann V Harth S Rabstein 2005 Factors modifying the association between hormone-replacement therapy and breast cancer risk Eur J Epidemiol 20 699 711 10.1007/s10654-005-0032-0
20. JC Barrett B Fry J Maller MJ Daly 2005 Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 263 265 10.1093/bioinformatics/bth457
21. M Kurzawski B Gawronska-Szklarz J Wrzesniewska A Siuda T Starzynska M Drozdzik 2006 Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients Eur J Clin Pharmacol 62 877 880 10.1007/s00228-006-0183-2
22. V Beral 2003 Breast cancer and hormone-replacement therapy in the million women study Lancet 362 419 427 10.1016/S0140-6736(03)14596-5
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333. doi: 10.1001/jama.288.3.321